BGPT: Paper Review: Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4

Explore by Goal

Quick Explanation Copied

Bottom-line: This Oncogene paper (Jia et al., DOI 10.1038/s41388-017-0072-4) presents reproducible biochemical evidence that PFKFB3 physically binds CDK4 (nuclear), stabilizes CDK4 protein via Hsp90–Cdc37 shielding from UPS degradation, requires PFKFB3 K147, and that disrupting that interaction sensitizes breast cancer cells to the CDK4 inhibitor palbociclib — mechanistically plausible and biologically meaningful but limited by small clinical sample set (n=30), modest mechanistic depth on how binding alters CDK4 conformation, and limited generality beyond breast models

Long Explanation

Visual paper analysis — Jia et al., Oncogene (DOI:10.1038/s41388-017-0072-4)

One-line finding:

PFKFB3 binds CDK4 via a conserved K147-containing motif, stabilizes CDK4 by promoting Hsp90–Cdc37 association and preventing ubiquitin–proteasome degradation, and disruption of this interaction increases sensitivity to palbociclib in breast cancer models

Raw counts: PFKFB3 and CDK4 high/low in clinical samples (n=30)

Data: Jia et al., IHC scoring; PFKFB3 high = 20/30, CDK4 high = 23/30 (cutoff IHC score≥4)

PFKFB3 vs CDK4 semi-quantitative IOD: reported correlation

Reported stats: Pearson correlation coefficient r = 0.555, P < 0.001, indicating moderate positive correlation between PFKFB3 and CDK4 IHC intensities

Mechanistic summary (visual-first)

Evidence for direct binding: IP–LC–MS identified CDK4 among PFKFB3 interactors; reciprocal co-IP and GST pull-down show direct interaction in vitro and in cells
Binding site: PFKFB3 aa131–154 required; K147→A (K147A) abolishes binding under stringent wash conditions, implicating K147 as critical contact
Functional consequence: PFKFB3 presence increases CDK4 half-life and decreases ubiquitination; knockdown or K147A expression increases CDK4 ubiquitination and reduces CDK4 protein without changing CDK4 mRNA, indicating post-translational regulation
Chaperone mechanism: PFKFB3 enhances assembly/association of Hsp90–Cdc37 with CDK4; PFKFB3 knockdown reduces CDK4–Hsp90/Cdc37 interaction, suggesting PFKFB3 promotes a protective chaperone complex that prevents ubiquitination and proteasomal clearance
Therapeutic link: Cells lacking PFKFB3 or expressing K147A mutant are more sensitive to palbociclib (lower IC50 in CD-DST and smaller xenograft tumors when treated), suggesting combined targeting of PFKFB3–CDK4 axis may sensitize tumors to CDK4/6 inhibitors

Critical appraisal — strengths & limitations

Strengths: convergent biochemical evidence (mass spec, reciprocal co-IP, direct GST pull-down), mapping to a specific residue (K147), functional ubiquitination/half-life assays, and translational tests (drug sensitivity + xenograft) provide a coherent story linking metabolic enzyme to cell-cycle control
Limitations / blindspots: small clinical sample (n=30) limits generalizability and statistical power for clinicopathological associations; lack of high-resolution structural data to show how K147 engages CDK4 or alters its surface/exposure to Cdc37/Hsp90; heavy reliance on overexpression/knockdown may mis-estimate stoichiometry and off-target effects; limited exploration of whether PFKFB3 kinase activity or F2,6BP production contributes to CDK4 stabilization (authors say basal OCR unchanged)
Interpretation caution: CDK4 stability is controlled by multiple regulators (C/EBPα, Hsp90–Cdc37, PRMTs, etc.); this work adds PFKFB3 as an additional regulator but does not exclude competing mechanisms; causality for clinical palbociclib response requires larger cohorts or controlled trials

High-value experiments to strengthen or falsify the claim

Solve co-crystal or cryo-EM structure (or AlphaFold-Multimer validated by mutagenesis) of the PFKFB3(aa131–154)–CDK4 complex to show atomic contacts for K147 and predict effects on CDK4 Hsp90/Cdc37 interface.
Use orthogonal endogenous perturbation: CRISPR knock-in K147A at the endogenous PFKFB3 locus in breast cancer lines (avoid overexpression) and measure CDK4 ubiquitination, half-life, and palbociclib sensitivity.
Test whether PFKFB3 enzymatic activity or F2,6BP production contributes: compare WT, catalytically-dead PFKFB3, and K147A constructs for CDK4 binding and stability.
Large patient cohorts (IHC and transcriptomics) and correlative palbociclib response datasets to test whether PFKFB3–CDK4 co-expression predicts clinical response.

Primary citation:

Author reviews (quick links)

Feedback:

Updated: February 21, 2026